SCI-ATT

SCINTOMICS Molecular, Applied Theranostics Technologies GmbH (SCI-att) is a prominent German radiopharmaceutical company specializing in cutting-edge theranostics solutions. Founded in 2018 as a subsidiary of Scintomics GmbH, the company focuses on the development and distribution of automated synthesis modules, precursors, and consumables for radiopharmaceutical production. Its core offerings include the GRP Module Series for radiosynthesis and a portfolio of innovative tracers such as PSMA I&T for prostate cancer and siFalin-TATE for neuroendocrine tumors. SCI-att provides comprehensive support for both proprietary tracer technology and non-IP protected precursors, ensuring a consistent supply for clinical and research applications. The company operates with a wholesale license and GDP certification, maintaining strategic partnerships with global distributors and manufacturers like Eckert & Ziegler.